Men's Sexual Health

Sexual health is a core component of overall health, quality of life, and well-being in men. Erectile dysfunction (ED) — the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity — is the most prevalent male sexual health concern in adult medicine, affecting approximately 30 million men in the United States. Despite its prevalence, ED remains significantly undertreated: epidemiological surveys consistently show that fewer than 25% of affected men seek or receive appropriate medical care. At Advanced Vitality Group, men's sexual health programs address this gap with comprehensive physician-supervised evaluation and evidence-based treatment protocols grounded in published clinical trial data.

The most important clinical insight about erectile dysfunction is that it is rarely an isolated problem. ED is frequently a vascular condition with the same underlying mechanisms as coronary artery disease — endothelial dysfunction, reduced arterial compliance, and impaired nitric oxide-mediated vasodilation. It is associated with testosterone deficiency, metabolic syndrome, diabetes, hypertension, and dyslipidemia. This means that addressing ED properly requires a comprehensive medical evaluation, not simply writing a prescription for a PDE5 inhibitor. Understanding and correcting the underlying biology is the foundation of our approach.

The Massachusetts Male Aging Study (MMAS) — a landmark epidemiological study of 1,290 men aged 40–70 — established the foundational data on ED prevalence in US men. The MMAS found that 52% of men in this age range had some degree of erectile dysfunction: 17% mild, 25% moderate, and 10% complete. Prevalence increased dramatically with age: the probability of complete ED tripled from 5% at age 40 to 15% at age 70. These figures were later updated in a meta-analysis of global ED prevalence (Ayta IA et al., BJU International, 1999), which projected that the global number of men with ED would reach 322 million by 2025.

The clinical consequence of these numbers is substantial. ED significantly impairs quality of life, relationship satisfaction, and psychological well-being in affected men and their partners. It is associated with depression at rates 3–4 times higher than in age-matched men without ED. And — critically — it represents a significant cardiovascular risk marker that, when identified and addressed in a comprehensive clinical program, creates an opportunity to intervene on multiple health dimensions simultaneously.

Penile erection is a neurovascular event. Sexual stimulation triggers the release of nitric oxide (NO) from cavernous nerves and vascular endothelium. NO activates guanylate cyclase, producing cyclic GMP (cGMP), which causes relaxation of cavernous smooth muscle and arterial dilation — allowing high-pressure inflow of blood that compresses venous outflow structures and produces rigidity. Phosphodiesterase type 5 (PDE5) degrades cGMP, terminating the erection.

This system fails when endothelial function is impaired. Atherosclerosis, hypertension, diabetes, smoking, dyslipidemia, and obesity all produce endothelial dysfunction — reducing NO production and impair arterial compliance. Because penile arteries (diameter ~1–2 mm) are smaller than coronary arteries (~3–4 mm), they develop hemodynamically significant atherosclerotic plaques earlier in the same vascular disease process. A pivotal 2003 study (Montorsi P et al., European Urology) found that among men presenting with acute coronary syndrome, 67% had experienced ED preceding their cardiac event — with an average interval of 38.8 months. This established ED as a potential cardiovascular sentinel event, often appearing 2–3 years before coronary disease becomes symptomatic.

The practical implication: ED is not merely a quality-of-life issue. It may be an early warning sign of subclinical cardiovascular disease, and its identification should trigger comprehensive cardiovascular risk assessment alongside sexual health treatment.